This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eisai Co., Ltd.
Drug Names(s): GPI 15715, fospropofol disodium, E2083, Aquavan
Description: AQUAVAN is a novel, water-soluble pro-drug of propofol, a commonly used intravenous anesthetic.
Deal Structure: Aquavan was developed by Guilford Pharmaceuticals. On October 3, 2005, MGI PHARMA closed its previously-announced acquisition of Guilford.
In December 2007, Eisai and MGI Pharma announced that they entered into a definitive merger agreement under which Eisai would acquire all of the outstanding shares of MGI Pharma for US$41.00 per share in an all cash transaction, for a total consideration of approximately $3.9 billion.
Partners: ProQuest Pharmaceuticals Inc.
Additional information available to subscribers only: